The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin. According to media reports, the company received complete response letters for Herzuma (trastuzumab; CT-P6) and Truxima (rituximab; […]
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s multiple sclerosis therapy Ocrevus. The Institute’s appraisal relates to the drug’s use for treating relapsing forms of multiple sclerosis in […]
Danish drugmaker Novo Nordisk has bought a global licence for EpiDestiny’s sickle cell disease (SCD) programme, EPI01. EPI01 is a novel, orally available, disease-modifying therapy, comprised of a fixed-dose formulation of a DNA methyl-transferase enzyme […]
Eli Lilly’ liver cancer treatment Cyramza (ramucirumab) has met its primary endpoint of overall survival (OS) and the secondary endpoint of progression-free survival (PFS) in the phase 3 Reach-2 study. The company has revealed the […]
Pfizer has signed an asset contribution agreement with Allogene Therapeutics for its Allogeneic CAR T immuno-oncology portfolio. Pfizer views this agreement as an attractive opportunity to support the continued development of allogeneic CAR T therapy […]